Cargando…

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bella, Ángela, Arrizabalaga, Leire, Di Trani, Claudia Augusta, Cirella, Assunta, Fernandez-Sendin, Myriam, Gomar, Celia, Russo-Cabrera, Joan Salvador, Rodríguez, Inmaculada, González-Gomariz, José, Alvarez, Maite, Teijeira, Álvaro, Medina-Echeverz, José, Hinterberger, Maria, Hochrein, Hubertus, Melero, Ignacio, Berraondo, Pedro, Aranda, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291657/ https://www.ncbi.nlm.nih.gov/pubmed/35859732 http://dx.doi.org/10.1080/2162402X.2022.2098657

Ejemplares similares

Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2023)

Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
por: Bella, Ángela, et al.
Publicado: (2021)

Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8(+) T cells eradicates peritoneal metastases in mouse models
por: Di Trani, Claudia Augusta, et al.
Publicado: (2022)

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
por: Tenesaca, Shirley, et al.
Publicado: (2021)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure
por: Di Trani, Claudia Augusta, et al.
Publicado: (2023)

CD70 encoded by modified vaccinia virus Ankara enhances CD8 T‐cell‐dependent protective immunity in MHC class II‐deficient mice
por: Bathke, Barbara, et al.
Publicado: (2018)

Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity
por: Fernandez-Sendin, Myriam, et al.
Publicado: (2021)

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
por: Medina-Echeverz, José, et al.
Publicado: (2019)

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
por: Cirella, Assunta, et al.
Publicado: (2023)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
por: Hinterberger, Maria, et al.
Publicado: (2023)

CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
por: Otano, Itziar, et al.
Publicado: (2021)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity
por: Lauterbach, Henning, et al.
Publicado: (2013)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice
por: Ardaiz, Nuria, et al.
Publicado: (2021)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
por: Kwon, Byungsuk
Publicado: (2015)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
por: Alvarez, Maite, et al.
Publicado: (2023)

The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus
por: Mak, Anselm, et al.
Publicado: (2019)

Myeloid-derived cells are key targets of tumor immunotherapy
por: Medina-Echeverz, José, et al.
Publicado: (2014)

Kinetic and Dynamic Computational Model-Based Characterization of New Proteins in Mice: Application to Interferon Alpha Linked to Apolipoprotein A-I
por: Parra-Guillen, Zinnia Patricia, et al.
Publicado: (2012)

Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death
por: Otano, Itziar, et al.
Publicado: (2020)

CD137-CD137L Interaction Regulates Atherosclerosis via Cyclophilin A in Apolipoprotein E-Deficient Mice
por: Li, Yuefeng, et al.
Publicado: (2014)

CD137L, a driver of harmful inflammation in the nervous system
por: Wong, Hiu Yi, et al.
Publicado: (2023)

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
por: Alvarez, Maite, et al.
Publicado: (2021)

mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
por: Olivera, Irene, et al.
Publicado: (2023)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
por: Morales-Kastresana, Aizea, et al.
Publicado: (2013)

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
por: Zeng, Qun, et al.
Publicado: (2019)

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers
por: Teijeira, Alvaro, et al.
Publicado: (2022)

ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes
por: Yanguas, Alba, et al.
Publicado: (2018)

Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases
por: Medina-Echeverz, José, et al.
Publicado: (2014)

Contribution of CD137L to Sensory Hypersensitivity in a Murine Model of Neuropathic Pain
por: Wakley, Alexa A., et al.
Publicado: (2018)

Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs
por: Zeng, Qun, et al.
Publicado: (2019)

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
por: Melero, Ignacio, et al.
Publicado: (2023)

Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction
por: Alkhamesi, Nawar A., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ldfrrkdeojjkhe9tdo5esncqpg